Daniel Collins, MD
Family Medicine · Coventry, RINPI 1104874320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 256 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$711
- Indivior Inc.$658
- AbbVie$564
- AstraZeneca$511
- Pfizer$388
- Inspire Medical Systems, Inc.$259
- plus $2K from 28 others
What the payments were for
- Travel & lodging$441%
- Food & beverage$4,99098%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $711 |
| Indivior Inc. | 25 | $658 |
| AbbVie(2 entities) | 31 | $564 |
| AstraZeneca | 28 | $511 |
| Pfizer | 35 | $388 |
| Inspire Medical Systems, Inc. | 13 | $259 |
| Novo Nordisk | 9 | $214 |
| Vanda Pharmaceuticals Inc. | 5 | $154 |
| Amarin Pharma, Inc. | 6 | $149 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| Exact Sciences | 5 | $114 |
| Amgen | 4 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $98 |
| Braeburn Inc. | 5 | $90 |
| Lilly USA, LLC | 4 | $88 |
| Merck | 4 | $84 |
| MDD US Operations, LLC | 3 | $78 |
| Paratek Pharmaceuticals, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Actelion Pharmaceuticals US, Inc. | 2 | $58 |
| Lundbeck LLC | 2 | $55 |
| Antares Pharma, Inc. | 2 | $52 |
| Edwards Lifesciences | 1 | $46 |
| Abbott | 2 | $45 |
| Verona Pharma, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Mylan Specialty L.p. | 2 | $41 |
| Genentech USA, Inc. | 2 | $41 |
| Theratechnologies Inc. | 1 | $39 |
| Dexcom, Inc. | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Myriad Women's Health, Inc. | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$104
How this compares
$5,083 in reported general payments places this provider in the 85th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $55,529 |
| FarxigaDapagliflozin Propanediol | 27 | $25,482 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 188 | $25,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $23,861 |
| SublocadeBuprenorphine | 11 | $22,759 |
| OzempicSemaglutide | 19 | $20,935 |
| JardianceEmpagliflozin | 14 | $11,117 |
| MotegrityPrucalopride Succinate | 11 | $6,467 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 165 | $6,127 |
| Oxycodone Hcl | 154 | $5,278 |
| Buprenorphine Hcl | 18 | $3,344 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $3,148 |
| Atorvastatin Calcium | 238 | $3,005 |
| Omeprazole | 118 | $2,346 |
| Alprazolam | 188 | $2,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $388 | $55,52982 claims |
| AstraZenecaFarxiga | $511 | $25,48227 claims |
| GSKTrelegy Ellipta | $711 | $23,86133 claims |
| Indivior Inc.Sublocade | $658 | $22,75911 claims |
| Novo NordiskOzempic | $214 | $20,93519 claims |
| Boehringer IngelheimJardiance | $42 | $11,11714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in Coventry
- Jose BenitezCoventry$2K
- Elena KwetkowskiCoventry$1K
- Gina la ProvaCumberland$778K
- Wilfredo Giordano-PerezJohnston$351K
- Martin MinerProvidence$124K
- Frank la FaziaWest Warwick$19K
- Jamiel AmbradWakefield$18K
- Jason AustinJohnston$15K
- Mary SutterPawtucket$13K
- Abdul Rahman Al HoutSmithfield$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.